Publications

Forthcoming

Foster H, Cobbs CS. Viruses and glioblastoma: affliction or opportunity? In: Robertson E, editor. Microbiome and Cancer. Current Cancer Research. New York: Humana Press. Forthcoming 2019.

2018

Piper KJ, Foster H, Susanto D, Maree CL, Thornton SD, Cobbs CS. Fatal Balamuthia mandrillaris brain infection associated with improper nasal lavage. International Journal of Infectious Diseases. 2018;77:18-22. doi:10.1016/j.ijid.2018.09.013. PMID: 30243910.

We present a case of a 69-year old female who presented with a chronic nasal skin rash, a new onset focal seizure, and a cerebral ring-enhancing lesion after a year of improper nasal irrigation. Despite aggressive and novel anti-amoebic treatment, she succumbed to a fatal Balamuthia mandrillaris brain infection.

2017

Foster H, Ulasov IV, Cobbs CS. Human cytomegalovirus-mediated immunomodulation: effects on glioblastoma progression. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. 2017;1868(1):273-276. doi:10.1016/j.bbcan.2017.05.006. PMID: 28554666.

The presence of human cytomegalovirus (HCMV) and glioblastoma multiforme (GBM), first established in 2002, has developed into an area of considerable interest and controversy. Numerous studies have found evidence of possible HCMV infection of GBM tumor cells as well as myriad onco- and immunomodulatory properties exhibited by HCMV antigens and transcripts, while recent reports have failed to detect HCMV particles in GBM and question the virus' role in tumor progression. This review highlights the known immunomodulatory properties of HCMV, independent of GBM infection status, that help drive the virus from peripheral blood into the vital tissues and subsequently dampen local immune response, assisting GBM tumors in evading immune surveillance and contributing to the disease's poor prognosis. Emerging antiviral approaches to treating GBM, including antiviral drugs and immunotherapies directed against HCMV, are also examined.

Ulasov IV, Foster H, Butters M, Yoon JG, Ozawa T, Nicolaides T, Figueroa X, Hothi P, Prados M, Butters J, Cobbs C. Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy. Journal of Neuro-Oncology. 2017;133(2):257-264. doi:10.1007/s11060-017-2440-x. PMID: 28434113.

Electromagnetic fields (EMF) in the radio frequency energy (RFE) range can affect cells at the molecular level. Here we report a technology that can record the specific RFE signal of a given molecule, in this case the siRNA of epidermal growth factor receptor (EGFR). We demonstrate that cells exposed to this EGFR siRNA RFE signal have a 30-70% reduction of EGFR mRNA expression and ~60% reduction in EGFR protein expression vs. control treated cells. Specificity for EGFR siRNA effect was confirmed via RNA microarray and antibody dot blot array. The EGFR siRNA RFE decreased cell viability, as measured by Calcein-AM measures, LDH release and Caspase 3 cleavage, and increased orthotopic xenograft survival. The outcomes of this study demonstrate that an RFE signal can induce a specific siRNA-like effect on cells. This technology opens vast possibilities of targeting a broader range of molecules with applications in medicine, agriculture and other areas.

Abstracts & Poster Presentations

2018

Foster H, Scanlan J, Piper K, Yoon JG, Cobbs C. Human cytomegalovirus seropositivity is associated with decreased survival in glioblastoma patients. Poster presented at: University of Cincinnati College of Medicine Research and Service Symposium; November 7, 2018; Cincinnati, OH.

Capizzano T, Foster H, Higgins Z, Howard P, Johns M, Kelder A, Langer M, Mendoza M, Moon J, Nickel M, O’Conor K, Perry A. Barriers to healthcare navigation: An inter-organizational analysis of key Cincinnati community stakeholders. Poster presented at: University of Cincinnati College of Medicine; April 25, 2018; Cincinnati, OH.

Thesis

Foster H. Breaking down barriers: Trilby as an entrance point to genius through the individual and gender transgression [master’s thesis]. [Seattle (WA)]: University of Washington; 2009.